Indian Gleevec purchasing agent in Anhui 13621079267 Indian Gleevec purchasing agent price

d=> %> DDDDD The price of Gleevec in India is between - The price of Gleevec produced in India is basically transparent. If it is sold too cheap, everyone must be careful. This tumor drug is very expensive and there are many fake drug workshops. Do not buy fake medicines to avoid delaying your condition.
Swiss-based Novartis Gleevec is currently in the Shandong Provincial Hospital. The price in Hong Kong, China, is about RMB-1.0 per box. The US price is about RMB-1.0 per box, while the price in other provinces in mainland China is as high as RMB-1.0 per box.
DDDDD
DDDDD What are the differences in ingredients and efficacy between the Indian Gleevec and the original Gleevec produced by the Swiss Novartis Company? Why are the prices of these two Gleevec so different? India itself is a country with a very developed generic drug industry. As soon as expensive drugs produced in Western countries are put on the market, under the protection of their own patent laws, India can imitate the same drugs, and the relative price will be several times lower. The Indian Gleevec Manufacturing Company Pharmaceutical Group is the second largest pharmaceutical group in India, so the effective content of the drugs is stable. Users can take it with confidence. The price of the Swiss version of Gleevec is around RMB 0.00 (capsules per box) of the genuine Indian Gleevec. The price of the Indian Gleevec is only that of the Swiss Gleevec/but the efficacy is the same. The Indian Gleevec is low in price and authentic. The efficacy gives cancer patients more hope, so Indian Gleevec is more suitable for China’s national conditions and easier for patients to accept. Integrity sales of various anti-cancer drugs, Gleevec, India, Iressa, India, Nexavar, India, Tarceva. While ensuring the quality of medicines, the price is as low as possible. Please contact new and old patients for information.
DDDDD
DDDDD functions and indications: chronic myelogenous leukemia, gastrointestinal stromal tumors. Gleevec (imatinib mesylate) is the world’s first approved tumorigenesis-related signaling Inhibitors.
DDDDD
DDDDD Usage and Dosage Starting dose: The recommended dose of imatinib mesylate for patients in the blast phase and accelerated phase of chronic myelogenous leukemia is/day. For patients in the chronic phase who have failed interferon therapy and those who cannot Children and adolescents with surgically resected or metastatic malignant gastrointestinal stromal tumors: There are no clinical data on the safety and efficacy of imatinib mesylate in patients under the age of 10. Dosage for patients with hepatic failure: The plasma concentration of imatinib mesylate may be elevated in patients with hepatic impairment. Therefore, caution should be exercised when using this drug in these patients. There are currently no recommendations for the use of imatinib mesylate in patients with hepatic impairment. Clinical data do not allow for recommendations for dose adjustment. Dosage in renal failure and elderly patients: Creatinine clearance is known to decrease with age and age has no significant effect on the pharmacokinetics of imatinib mesylate as it has not been studied in Clinical trials have been conducted in patients with renal impairment and no dosage adjustment recommendations can be made.

_ d=_>Inquiry unit